Spry review

A price with no period on it is the least comparable number in this whole category, and Spry publishes five of them. The cards give an amount and nothing else — not a month, not a supply length, not a vial count — so a reader arriving from a comparison naturally reads them as monthly rates, because that is what everything around them is. The company does say what the cycle is, and it says it clearly, but it says it inside a question about what happens after you order: you dose weekly for four weeks, and then you are rebilled and the next vial ships. Four weeks is not a month. Thirteen of those cycles fit in a year, so budgeting twelve of these figures leaves you short by roughly one charge, and the gap grows the longer you stay on treatment. That is why neither figure is treated as a monthly rate here. What the page does well is the clinical part. The screening criteria are named specifically — the thyroid and endocrine histories, the pancreatitis history, the pregnancy exclusion, the interacting medications — rather than gestured at, review is promised within a day by a named clinician type, and the company states a target rather than a testimonial. If you want a prescriber engaged with your case you will find more evidence of that here than the pricing presentation suggests.

Vs median

Not comparable — no per-month rate is published — the verified string carries no monthly figure

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

Spry does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

A price with no period on it is the least comparable number in this whole category, and Spry publishes five of them. The cards give an amount and nothing else — not a month, not a supply length, not a vial count — so a reader arriving from a comparison naturally reads them as monthly rates, because that is what everything around them is. The company does say what the cycle is, and it says it clearly, but it says it inside a question about what happens after you order: you dose weekly for four weeks, and then you are rebilled and the next vial ships. Four weeks is not a month. Thirteen of those cycles fit in a year, so anyone budgeting twelve of these figures will be short by roughly one charge, and the gap grows the longer someone stays on treatment. That is the reason neither figure is treated as a monthly rate here. What the page does well is the clinical part. The screening criteria are named specifically — the thyroid and endocrine histories, the pancreatitis history, the pregnancy exclusion, the interacting medications — rather than gestured at, review is promised within a day by a named clinician type, and the company states a target rather than a testimonial. A reader who wants a prescriber engaged with their case will find more evidence of that here than the pricing presentation suggests.

No figure on the site carries a billing period, so none can be compared directly.

• The real cycle is four weeks, which is thirteen charges a year rather than twelve.
• No dose sits behind any figure.

Spry is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Low dose vs full dose
• The true annual cost of a plan